Akari Therapeutics, Plc
Advancing Next-Generation Antibody Drug Conjugates Designed with Novel ImmunoOncology Payloads
17 employees · est. 2015 · London, United Kingdom
Scioderm, Inc., an Amicus Therapeutics Company
Dedicated to pioneering topical solutions for treating chronic skin diseases.
2 employees · est. 2012 · Durham, United States
Scioderm, Inc., an Amicus Therapeutics Company is the older company (2015 vs 2012); Akari Therapeutics, Plc is the larger of the two.
Side-by-Side Comparison
| Metric | Akari Therapeutics, Plc | Scioderm, Inc., an Amicus Therapeutics Company |
|---|---|---|
| Founded | ||
| Founded | 2015 | 2012 older |
| Headquarters | ||
| Headquarters | London, United Kingdom | Durham, United States |
| Employees | ||
| Employees | 17 larger | 2 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health Care | Biotechnology, Health Care, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Series B |
| Total Funding | ||
| Total Funding | $114.25M | $37.00M |
| Funding Rounds | ||
| Funding Rounds | 5 | 3 |
| Services | ||
| Services | Not tracked yet | Development of Medicines for Rare Diseases, Clinical Trials Management, Patient Advocacy and Support, Research and Pipeline Initiatives |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with Rare Diseases, Healthcare Providers, Medical Researchers |
| Taxonomy | ||
| Taxonomy | Autoimmune Diseases, Inflammatory Diseases, Nomacopan, Clinical Trials, Pediatric Medicine, Hematopoietic Stem Cell Transplant, Orphan Drug Designation, Fast Track Designation, Rare Pediatric Disease Designation, European Commission, Pre-clinical Research, Complement C5 Activation, Leukotriene B4 Activity, Geographic Atrophy | Rare Genetic Diseases, Clinical-stage Pharmaceutical, Topical Solutions, Chronic Skin Diseases, Acquisition, Investigational Treatment, Patient-dedicated, Phase 3 Clinical Study, Efficacy And Safety, Data Sharing, Medical Needs, Epidermolysis Bullosa, Global Company, Publicly Traded |
| Website | ||
| Website | akaritx.com | sderm.com |
About Akari Therapeutics, Plc
Akari Therapeutics, Plc is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The company's pipelin...
About Scioderm, Inc., an Amicus Therapeutics Company
Scioderm, Inc., an Amicus Therapeutics company, is recognized for its dedication to pioneering topical solutions addressing chronic skin diseases. Initially founded in 2012, this biotech company was later acquired by Amicus Therapeutics in September 2015, aligning with Amicus's mission to deliver in...
We will tell you when either one moves
BounceWatch watches Akari Therapeutics, Plc and Scioderm, Inc., an Amicus Therapeutics Company for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Akari Therapeutics, Pl... and Scioderm, Inc., an Ami... — by email.
Frequently Asked Questions
Compare Akari Therapeutics, Plc with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Akari Therapeutics, Plc on 9 Jun 2026, and Scioderm, Inc., an Amicus Therapeutics Company on 13 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
